Loading clinical trials...

NOT_YET_RECRUITING

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

NCT06656234•Ruijin Hospital

Summary

The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Be diagnosed as R/R DLBCL
•Participants who will be treated with glofitamab (known as being recommended and having the intention to be treated with glofitamab at the time of signing informed consent) or have initiated glofitamab treatment within 6 months prior to enrollment and after the indication approval will be observed in this study.

Exclusion Criteria

•Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Locations (1)

Ruijin Hospital, Shanghai JiaoTong University School of Medicine

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

October 30, 2024

Primary Completion Date

September 15, 2027

Completion Date

September 15, 2028

Last Updated

October 24, 2024

Enrollment

200

ESTIMATED participants

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

Glofitamab

DRUG

Obinutuzumab

DRUG

Contacts

Weili Zhao

CONTACT

008602164370045 zwl_trial@163.com

DALY II USA/ MB-CART2019.1 for DLBCL

NCT04792489

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell Lymphoma+6 more

View study

COMPLETEDPHASE1

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989

Advanced Solid TumorNon Small Cell Lung Cancer (NSCLC)+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 24, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

Inclusion Criteria

Exclusion Criteria

DALY II USA/ MB-CART2019.1 for DLBCL

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Dynamic CtDNA-guided Targeted Therapy in DLBCL

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma